Division of Urology, The Hospital for Sick Children, Toronto, ON, Canada.
Department of Pediatric Urology, Children's Healthcare of Atlanta, Atlanta, GA, USA.
J Pediatr Urol. 2021 Aug;17(4):589.e1-589.e6. doi: 10.1016/j.jpurol.2021.07.012. Epub 2021 Jul 17.
Vesicoureteral reflux (VUR) after renal transplant in the pediatric population may be associated with an increased incidence of urinary tract infection (UTIs) leading to increased morbidity, including graft dysfunction and graft loss. The non-orthotopic location of the transplanted ureter, and lack of submucosal tunnel may pose challenges in correcting the VUR using endoscopic injection techniques. Herein we report the results of a systematic review evaluating the outcomes of endoscopic treatment of VUR using Deflux® in this population.
Pubmed and Embase databases were searched from October 2001 to April 2019. Full-text English articles involving patients less than 18 years old at the time of transplant, with a diagnosis of VUR post-transplantation, who underwent Deflux® treatment were included. Figure 1 outlines our PRISMA-compliant search strategy.
We found 6 eligible studies describing Deflux® treatment outcomes in 67 pediatric patients with post-transplant VUR where voiding cystourethrogram (VCUG) confirmed the diagnosis and resolution of VUR. The mean success rate was 36.8%. Ureteral obstruction occurred in 7/67 cases (10.4%). In all these 7 cases of obstruction, ureteric stenting was the initial management, but was only successful in 1 patient. Open ureteroneocystostomy (UNC) was performed in 4/7 cases, while 2/7 were managed expectantly (unknown outcomes). Persistent VUR with UTI despite Deflux® were reported in 20 out of 67 cases. Of these, 7 were managed with prophylactic antibiotics, and 13 with UNC. Success rates were consistently low for UNC after failed Deflux® in comparison to redo UNC in transplant ureters without prior injection.
Low success rates are seen following injection techniques for VUR after pediatric renal transplant. Although an appealing option, Deflux® may prove counterintuitive due to the high rate of obstruction and suboptimal results if open reimplantation is required. A multi-institutional prospective study with a larger population size may further elucidate these results.
小儿肾移植后发生的输尿管反流(VUR)可能与尿路感染(UTI)发生率增加有关,从而导致发病率增加,包括移植物功能障碍和移植物丢失。移植输尿管的非原位位置和缺乏黏膜下隧道可能会对使用内镜注射技术矫正 VUR 造成挑战。在此,我们报告了一项系统评价的结果,该评价评估了在该人群中使用 Deflux®治疗 VUR 的内镜治疗结果。
我们从 2001 年 10 月至 2019 年 4 月在 Pubmed 和 Embase 数据库中进行了搜索。纳入的全文英文文章涉及在移植时年龄小于 18 岁的患者,这些患者患有移植后 VUR,并接受了 Deflux®治疗。图 1 概述了我们符合 PRISMA 标准的搜索策略。
我们发现了 6 项符合条件的研究,这些研究描述了 67 例小儿肾移植后 VUR 患者使用 Deflux®治疗的结果,排尿性膀胱尿道造影(VCUG)证实了 VUR 的诊断和缓解。平均成功率为 36.8%。在 67 例病例中,有 7 例(10.4%)发生输尿管梗阻。在所有这 7 例梗阻中,初始治疗均采用输尿管支架,但仅在 1 例患者中成功。对 4/7 例病例进行了开放性输尿管肾盂吻合术(UNC),而 2/7 例病例进行了保守治疗(未知结果)。尽管使用了 Deflux®,但仍有 20 例(67 例中的 20 例)患者存在持续性 VUR 和尿路感染。其中,7 例预防性使用抗生素,13 例接受 UNC 治疗。与未接受过注射治疗的移植输尿管再次 UNC 相比,Deflux® 治疗失败后 UNC 的成功率一直较低。
小儿肾移植后使用注射技术治疗 VUR 的成功率较低。尽管 Deflux®是一种有吸引力的选择,但由于梗阻率高且如果需要开放性再植入则结果不理想,因此可能会适得其反。一项具有更大人群规模的多机构前瞻性研究可能会进一步阐明这些结果。